⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Supplementary Results 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Mohamed A. Gouda Filip Jankú Ying Yuan Leylah Drusbosky Alice P. Chen Xiaofeng Zheng Keyur P. Patel Stanley R. Hamilton Mark J. Routbort James V. Tricoli P. Mickey Williams A. John Iafrate Jeffrey Sklar Brent Coffey Richard F. Little Carlos L. Arteaga Peter J. O’Dwyer Keith T. Flaherty Lyndsay N. Harris Funda Meric‐Bernstam

View at Publisher

Ask AI

Bookmark

Share

Key Points

The analysis of tumor tissue and plasma DNA confirmed impactful genetic insights for treatment plans.
Results indicate that plasma DNA genotyping can reliably inform actionability across various cancer types.
Detailed findings emphasize the importance of integrating tumor tissue and plasma DNA data for targeted therapies.
The NCI-MATCH trial provides a framework for understanding the genetic basis of cancer treatment outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Supplementary results reveal insights on tumor tissue and plasma DNA genotyping actionability in patients.

Abstract

Supplementary Results 1. Detailed results about actionability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gouda et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcbcd https://doi.org/10.1158/1078-0432.30363456

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
2Supplementary Figure 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
3Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
4Supplementary Figure 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
5Supplementary Figure 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025

More related papers

Supplementary Figure 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025
Supplementary Figure 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)2025